Buy Full Version
"Cancer Pain Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Cancer Pain Market by Drug Type (Opioids, Non-Opioids, and Nerve Blockers) and Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Pharmaceuticals	LI_185123	Pages: 177	Dec 2018 \| 2940 Views
Author(s) : Onkar Sumant & Sayali Shinde	Tables: 89	Charts: 34	Formats*:

Cancer Pain Market Overview:

The global cancer pain market generated $5,285 million in 2017, and is projected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

Cancer pain can be due to the disease condition itself or may be due to the treatments such as surgeries, chemotherapy, and others. There are various drugs used for the management of cancer pain. Surge in prevalence of cancer across geographies and increase in adoption of cancer pain drugs for treatment of mild to moderate pain drive the growth of the global cancer pain market. Furthermore, increased healthcare expenditures, increase in government initiatives to alleviate cancer, rise in public awareness and advance cancer pain therapeutics, and surge in geriatric population are expected to boost the growth of the global market. However, adverse effect associated with the use of cancer pain drugs is projected to restrain the market growth.

The global cancer pain market is segmented based on drug type, disease indication, and region. Based on drug type, the market is segmented as opioids, non-opioids, and nerve blockers. According to disease indication, the market is categorized into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

Get more information on this report : Request Sample Pages

Segment review

Based on drug type, the global cancer pain market is segmented into opioids, non-opioids, and nerve blockers. These drugs are used depending on the severity of pain for instance strong opioids are used preferably in case of severe pain whereas non-opioids, such as acetaminophen and NSAIDs, are preferred to treat mild to moderate cancer pain. Presently, the opioid segment is the major revenue contributor and is estimated to exhibit significant market growth during the forecast period due to rise in prevalence of severe cancer pain, increase in adoption of opioids in the management of cancer pain, and strong presence of pipeline drugs. In 2018, Daiichi Sankyo Co., Ltd. for instance launched Naruvein injection, an opioid analgesic for cancer pain treatment. It also launched Narurapid immediate release tablets and Narusus once-daily extended-release tablets, both opioid analgesics for the treatment of cancer pain in 2017.

Get more information on this report : Request Sample Pages

Based on disease indication, the global cancer pain market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. Presently, the lung cancer segment is a major revenue contributor and is anticipated to dominate the market during the forecast period. Higher prevalence of lung cancer and surge in the use of cancer painkillers to get relief from pain majorly drive the growth of this segment. In addition, increase in geriatric population, surge in cigarette smoking population, and advancements in diagnostic techniques for lung cancer are expected to boost the growth of the global market.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific cancer pain market

Asia-Pacific presents lucrative opportunities for the key players operating in the cancer pain drugs market due to large population base, rise in availability of pain therapeutics, surge in incidence of cancer, and improvement of healthcare infrastructure. China, Japan, and India have high prevalence of cancer, which is expected to drive the demand for the cancer pain market in the future. However, healthcare insurance providers do not cover the entire expenses for the treatment of cancer. This factor is estimated to hamper the market growth in the Asia-Pacific region.

Get more information on this report : Request Sample Pages

The key players profiled in this report include Aoxing Pharmaceutical Company, Inc., BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grnenthal Pharma GmbH & Co. KG, Hisamitsu Pharmaceutical Co., Inc., Insys Therapeutics, Inc., Mundipharma International Limited, Orexo AB, Pfizer Inc., and Teva Pharmaceutical Industries Limited.

Key Benefits for Cancer Pain Market:

The study presents an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Cancer Pain Key Market Segments:

By Drug Type

Opioids
Non-Opioids
Nerve Blockers

By Application

Lung Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

CHAPTER 1: INTRODUCTION

1.1.   Report description
1.2.   Key benefits for stakeholders
1.3.   Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1.   Secondary research
1.4.2.   Primary research
1.4.3.   Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top player positioning

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1.   Rise in incidence of cancer across the globe
3.3.1.2.   Surge in global geriatric population
3.3.1.3.   Increase in healthcare expenditure worldwide

3.3.2. Restraints

3.3.2.1. Adverse effects associated with the use of drugs employed in cancer pain management

3.3.3. Opportunities

3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in emerging markets

3.3.4. Impact analyses

CHAPTER 4: CANCER PAIN MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Opioids

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Morphine

4.2.2.1.1. Market size and forecast

4.2.2.2. Fentanyl

4.2.2.2.1. Market size and forecast

4.2.2.3. Others

4.2.2.3.1. Market size and forecast

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Non-opioids

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Acetaminophen

4.3.2.1.1. Market size and forecast

4.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

4.3.2.2.1. Market size and forecast

4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

4.4. Nerve blockers

4.4.1.   Key market trends, growth factors, and opportunities
4.4.2.   Market size and forecast, by region
4.4.3.   Market analysis, by country

CHAPTER 5: CANCER PAIN MARKET, BY DISEASE INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Lung cancer

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Colorectal cancer

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Breast cancer

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Prostate cancer

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Blood cancer

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

5.7. Others

5.7.1. Market size and forecast
5.7.2. Market analysis, by country

CHAPTER 6: CANCER PAIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by type
6.2.2.1.2. U.S. market size and forecast, by disease indication

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by type
6.2.2.2.2. Canada market size and forecast, by disease indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico market size and forecast, by type
6.2.2.3.2. Mexico market size and forecast, by disease indication

6.2.3. Market size and forecast, by type
6.2.4. Market size and forecast, by disease indication

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by type
6.3.2.1.2. Germany market size and forecast, by disease indication

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by type
6.3.2.2.2. France market size and forecast, by disease indication

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by type
6.3.2.3.2. UK market size and forecast, by disease indication

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by type
6.3.2.4.2. Italy market size and forecast, by disease indication

6.3.2.5. Spain

6.3.2.5.1. Spain market size and forecast, by type
6.3.2.5.2. Spain market size and forecast, by disease indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe market size and forecast, by type
6.3.2.6.2. Rest of Europe market size and forecast, by disease indication

6.3.3. Market size and forecast, by type
6.3.4. Market size and forecast, by disease indication

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by type
6.4.2.1.2. Japan market size and forecast, by disease indication

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by type
6.4.2.2.2. China market size and forecast, by disease indication

6.4.2.3. Australia

6.4.2.3.1. Australia market size and forecast, by type
6.4.2.3.2. Australia market size and forecast, by disease indication

6.4.2.4. India

6.4.2.4.1. India market size and forecast, by type
6.4.2.4.2. India market size and forecast, by disease indication

6.4.2.5. Rest of Asia-Pacific

6.4.2.5.1. Rest of Asia- Pacific market size and forecast, by type
6.4.2.5.2. Rest of Asia- Pacific market size and forecast, by disease indication

6.4.3. Market size and forecast, by type
6.4.4. Market size and forecast, by disease indication

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil market size and forecast, by type
6.5.2.1.2. Brazil market size and forecast, by disease indication

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia market size and forecast, by type
6.5.2.2.2. Saudi Arabia market size and forecast, by disease indication

6.5.2.3. South Africa

6.5.2.3.1. South Africa market size and forecast, by type
6.5.2.3.2. South Africa market size and forecast, by disease indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA market size and forecast, by type
6.5.2.4.2. Rest of LAMEA market size and forecast, by disease indication

6.5.3. Market size and forecast, by type
6.5.4. Market volume and forecast, by disease indication

CHAPTER 7: COMPANY PROFILES

7.1. AOXING PHARMACEUTICAL COMPANY, INC.

7.1.1.   Company overview
7.1.2.   Company snapshot
7.1.3.   Operating business segments
7.1.4.   Product Portfolio
7.1.5.   Business performance

7.2. BIODELIVERY SCIENCES INTERNATIONAL, INC.

7.2.1.   Company overview
7.2.2.   Company snapshot
7.2.3.   Operating business segments
7.2.4.   Product Portfolio
7.2.5.   Business performance

7.3. DAIICHI SANKYO CO., LTD.

7.3.1.   Company overview
7.3.2.   Company snapshot
7.3.3.   Product Portfolio
7.3.4.   Business performance
7.3.5.   Key strategic moves and developments

7.4. GRÜNENTHAL PHARMA GmbH & CO. KG

7.4.1.   Company overview
7.4.2.   Company snapshot
7.4.3.   Product Portfolio

7.5. HISAMITSU PHARMACEUTICAL CO., INC.

7.5.1.   Company overview
7.5.2.   Company snapshot
7.5.3.   Operating business segments
7.5.4.   Product portfolio
7.5.5.   Business performance

7.6. INSYS THERAPEUTICS, INC.

7.6.1.   Company overview
7.6.2.   Company snapshot
7.6.3.   Operating business segments
7.6.4.   Product portfolio
7.6.5.   Business performance

7.7. MUNDIPHARMA INTERNATIONAL LIMITED

7.7.1.   Company overview
7.7.2.   Company snapshot
7.7.3.   Product Portfolio

7.8. OREXO AB

7.8.1.   Company overview
7.8.2.   Company snapshot
7.8.3.   Operating business segments
7.8.4.   Product Portfolio
7.8.5.   Business performance

7.9. PFIZER INC.

7.9.1.   Company overview
7.9.2.   Company snapshot
7.9.3.   Operating business segments
7.9.4.   Product Portfolio
7.9.5.   Business performance

7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.10.1.   Company overview
7.10.2.   Company snapshot
7.10.3.   Operating business segments
7.10.4.   Product Portfolio
7.10.5.   Business performance

LIST OF TABLES

TABLE 01.   GLOBAL CANCER PAIN MARKET, BY DRUG TYPE, 2017–2025 ($MILLION)
TABLE 02.   OPIOIDS MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 03.   OPIOIDS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 04.   NON-OPIOIDS MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 05.   NON-OPIOIDS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 06.   NERVE BLOCKERS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 07.   GLOBAL CANCER PAIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 08.   LUNG CANCER PAIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 09.   COLORECTAL CANCER PAIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 10.   BREAST CANCER PAIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 11.   PROSTATE CANCER PAIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 12.   BLOOD CANCER PAIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 13.   CANCER PAIN MARKET FOR OTHER DISEASE INDICATION, BY REGION, 2017–2025 ($MILLION)
TABLE 14.   CANCER PAIN MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)
TABLE 15.   NORTH AMERICA CANCER PAIN MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 16.   U.S. CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 17.   U.S. CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 18.   CANADA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 19.   CANADA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 20.   MEXICO CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 21.   MEXICO CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 22.   NORTH AMERICA CANCER PAIN MARKET REVENUE, BY TYPE, 2017–2025 ($MILLION)
TABLE 23.   NORTH AMERICA CANCER PAIN MARKET REVENUE, BY DISEASE INDICATION, 2017–2025 ($MILLION)
TABLE 24.   EUROPE CANCER PAIN MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 25.   GERMANY CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 26.   GERMANY CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 27.   FRANCE CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 28.   FRANCE CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 29.   UK CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 30.   UK CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 31.   ITALY CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 32.   ITALY CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 33.   SPAIN CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 34.   SPAIN CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 35.   REST OF EUROPE CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 36.   REST OF EUROPE CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 37.   EUROPE CANCER PAIN MARKET REVENUE, BY TYPE, 2017–2025 ($MILLION)
TABLE 38.   EUROPE CANCER PAIN MARKET REVENUE, BY DISEASE INDICATION, 2017–2025 ($MILLION)
TABLE 39.   ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 40.   JAPAN CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 41.   JAPAN CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 42.   CHINA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 43.   CHINA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 44.   AUSTRALIA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 45.   AUSTRALIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 46.   INDIA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 47.   INDIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 48.   REST OF ASIA- PACIFIC CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 49.   REST OF ASIA- PACIFIC CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 50.   ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY TYPE, 2017–2025 ($MILLION)
TABLE 51.   ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY DISEASE INDICATION, 2017–2025 ($MILLION)
TABLE 52.   LAMEA CANCER PAIN MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 53.   BRAZIL CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 54.   BRAZIL CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 55.   SAUDI ARABIA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 56.   SAUDI ARABIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 57.   SOUTH AFRICA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 58.   SOUTH AFRICA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 59.   REST OF LAMEA CANCER PAIN MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 60.   REST OF LAMEA CANCER PAIN MARKET, BY DISEASE INDICATION, 2016–2023 ($MILLION)
TABLE 61.   LAMEA CANCER PAIN MARKET REVENUE, BY TYPE, 2017–2025 ($MILLION)
TABLE 62.   LAMEA CANCER PAIN MARKET VOLUME, BY DISEASE INDICATION, 2017–2025 (UNITS)
TABLE 63.   AOXING PHARM: COMPANY SNAPSHOT
TABLE 64.   AOXING PHARM: OPERATING SEGMENTS
TABLE 65.   AOXING PHARM: PRODUCT PORTFOLIO
TABLE 66.   BDSI: COMPANY SNAPSHOT
TABLE 67.   BDSI: OPERATING SEGMENTS
TABLE 68.   BDSI: PRODUCT PORTFOLIO
TABLE 69.   DAIICHI SANKYO: COMPANY SNAPSHOT
TABLE 70.   DAIICHI SANKYO: PRODUCT PORTFOLIO
TABLE 71.   GRÜNENTHAL: COMPANY SNAPSHOT
TABLE 72.   GRÜNENTHAL: PRODUCT PORTFOLIO
TABLE 73.   HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 74.   HISAMITSU PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 75.   HISAMITSU PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 76.   INSYS: COMPANY SNAPSHOT
TABLE 77.   INSYS: OPERATING SEGMENTS
TABLE 78.   INSYS: PRODUCT PORTFOLIO
TABLE 79.   MUNDIPHARMA: COMPANY SNAPSHOT
TABLE 80.   MUNDIPHARMA: PRODUCT PORTFOLIO
TABLE 81.   OREXO: COMPANY SNAPSHOT
TABLE 82.   OREXO: OPERATING SEGMENTS
TABLE 83.   OREXO: PRODUCT PORTFOLIO
TABLE 84.   PFIZER: COMPANY SNAPSHOT
TABLE 85.   PFIZER: OPERATING SEGMENTS
TABLE 86.   PFIZER: PRODUCT PORTFOLIO
TABLE 87.   TEVA: COMPANY SNAPSHOT
TABLE 88.   TEVA: OPERATING SEGMENTS
TABLE 89.   TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.   GLOBAL CANCER PAIN MARKET SEGMENTATION
FIGURE 02.   TOP INVESTMENT POCKETS
FIGURE 03.   TOP PLAYER POSITIONING, 2017
FIGURE 04.   WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05.   IMPACT ANALYSES
FIGURE 06.   MORPHINE MARKET FOR CANCER PAIN, 2017–2025 ($MILLION)
FIGURE 07.   FENTANYL MARKET FOR CANCER PAIN, 2017–2025 ($MILLION)
FIGURE 08.   OTHERS MARKET FOR CANCER PAIN, 2017–2025 ($MILLION)
FIGURE 09.   COMPARATIVE ANALYSIS OF OPIOIDS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 10.   ACETAMINOPHEN MARKET FOR CANCER PAIN, 2017–2025 ($MILLION)
FIGURE 11.   NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR CANCER PAIN, 2017–2025 ($MILLION)
FIGURE 12.   COMPARATIVE ANALYSIS OF NON-OPIOIDS, MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 13.   COMPARATIVE ANALYSIS OF NERVE BLOCKERS MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 14.   COMPARATIVE ANALYSIS OF LUNG CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 15.   COMPARATIVE ANALYSIS OF COLORECTAL CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16.   COMPARATIVE ANALYSIS OF BREAST CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17.   COMPARATIVE ANALYSIS OF PROSTATE CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18.   COMPARATIVE ANALYSIS OF BLOOD CANCER PAIN MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19.   COMPARATIVE ANALYSIS OF CANCER PAIN MARKET FOR OTHER INDICATION MARKET, BY COUNTRY, 2017 & 2025 (%)
FIGURE 20.   AOXING PHARM: REVENUE, 2015–2017 ($MILLION)
FIGURE 21.   BDSI: NET SALES, 2015–2017 ($MILLION)
FIGURE 22.   DAIICHI SANKYO: NET SALES, 2015–2017 ($MILLION)
FIGURE 23.   HISAMITSU PHARMACEUTICAL REVENUE, 2015–2017 ($MILLION)
FIGURE 24.   HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY BUSINESS SEGMENT, 2017 (%)
FIGURE 25.   HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 26.   INSYS: NET SALES, 2015–2017 ($MILLION)
FIGURE 27.   OREXO: REVENUE, 2015–2017 ($MILLION)
FIGURE 28.   OREXO: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 29.   PFIZER: REVENUE, 2015–2017 ($MILLION)
FIGURE 30.   PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31.   PFIZER: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 32.   TEVA: REVENUE, 2015–2017 ($MILLION)
FIGURE 33.   TEVA: REVENUE BY SEGMENT, 2017 (%)
FIGURE 34.   TEVA: REVENUE SHARE BY REGION, 2017 (%)

Cancer pain occurs due to cancer itself or may be due to the associated treatments such as chemotherapy, surgeries, and other cancer therapies.

The adoption of cancer pain drugs is expected to increase in the near future majorly due to rise in prevalence of cancer across the globe. Moreover, surge in demand for advanced therapeutics for the treatment of cancer pain due to high unmet medical needs propels the growth of the global cancer pain market.

Rise in incidence of cancer in the developing countries, surge in R&D studies to develop ideal cancer pain therapeutics, wide availability of drugs for management of cancer pain, higher number of unmet needs for the management of severe cancer pain, and growth in adoption of cancer pain medications are projected to supplement the market growth during the forecast period. However, complications associated with the use of cancer pain medications are expected to hinder the market growth.

North America is expected to remain dominant during the forecast period due to surge in use of cancer pain drugs, owing to higher number of cancer affected patient population with developed healthcare infrastructure. In addition, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period due to rise in demand for ideal cancer pain therapeutics, owing to increase in incidence of different forms of cancer.